LSFP · Lftd Partners Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $36.92M | $37.33M | $51.61M | $57.42M | $31.66M | $5.34M |
| Cost of Revenue | $24.30M | $24.57M | $31.91M | $36.42M | $15.72M | $3.41M |
| Gross Profit | $12.62M | $12.75M | $19.70M | $20.99M | $15.94M | $1.94M |
| R&D | - | - | $19.8K | $19.8K | - | - |
| SG&A | - | - | - | - | - | $134.0K |
| Total Operating Expenses | $11.71M | $13.53M | $17.29M | $11.18M | $3.46M | - |
| D&A | $552.9K | $520.6K | $425.6K | $16.4K | $90.1K | $16.4K |
| Operating Income | $913.2K | ($773.5K) | $2.41M | $9.81M | $7.78M | ($1.52M) |
| Interest Expense | - | - | $110.5K | $120.2K | $142.4K | $65.2K |
| Income Tax | $432.8K | $524.4K | $598.1K | $2.80M | $7.17M | $0 |
| Net Income | ($24.86M) | ($1.86M) | $2.16M | $7.20M | $5.80M | ($1.53M) |
| EPS - Basic | ($1.68) | ($0.13) | $0.15 | $0.51 | ($0.29) | - |
| EPS - Diluted | ($1.68) | ($0.13) | $0.13 | $0.45 | ($0.29) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.77M | $2.15M | $4.36M | $3.53M | $1.60M | $439.1K |
| Accounts Receivable | $2.53M | $2.36M | $3.59M | $2.41M | $3.46M | $0 |
| Inventory | $10.96M | $9.32M | $10.17M | $6.02M | $3.81M | $641.2K |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $15.69M | $16.93M | $21.67M | $13.85M | $13.15M | $3.26M |
| Total Assets | $19.27M | $47.32M | $51.35M | $41.13M | $39.42M | $27.83M |
| Current Liabilities | $5.16M | $6.08M | $8.69M | $6.21M | $11.91M | $2.31M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $6.64M | $9.81M | $12.53M | $6.59M | $11.96M | $6.21M |
| Stockholders' Equity | $12.63M | $37.50M | $38.82M | $34.54M | $27.46M | $21.62M |
| Retained Earnings | ($28.84M) | ($3.97M) | ($2.10M) | ($4.24M) | ($11.41M) | ($17.14M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.32M | ($960.1K) | $638.9K | $3.04M | $5.62M | ($338.0K) |
| Investing Cash Flow | ($121.6K) | ($479.6K) | ($2.52M) | ($916.1K) | ($446.7K) | ($3.51M) |
| Financing Cash Flow | ($2.58M) | ($771.0K) | $3.70M | ($193.4K) | ($4.01M) | ($98.0K) |
| CapEx | $121.6K | $313.8K | $789.7K | $916.1K | $368.2K | $70.1K |
| Free Cash Flow | $1.20M | ($1.27M) | ($150.7K) | $2.12M | $5.25M | ($408.2K) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 34.2% | 34.2% | 38.2% | 36.6% | 50.4% | 36.2% |
| Operating margin | 2.5% | -2.1% | 4.7% | 17.1% | 24.6% | -28.4% |
| EBITDA margin | 4.0% | -0.7% | 5.5% | 17.1% | 24.9% | -28.1% |
| Net margin | -67.3% | -5.0% | 4.2% | 12.5% | 18.3% | -28.7% |
| Free cash flow margin | 3.2% | -3.4% | -0.3% | 3.7% | 16.6% | -7.6% |
| FCF / Net income | -0.05 | 0.69 | -0.07 | 0.29 | 0.91 | 0.27 |
| R&D / Revenue | - | - | 0.0% | 0.0% | - | - |
| SG&A / Revenue | - | - | - | - | - | 2.5% |
| Effective tax rate | - | - | 21.7% | 28.0% | 55.3% | - |
| Return on assets | -129.0% | -3.9% | 4.2% | 17.5% | 14.7% | -5.5% |
| Return on equity | -196.8% | -5.0% | 5.6% | 20.8% | 21.1% | -7.1% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 3.04 | 2.78 | 2.49 | 2.23 | 1.10 | 1.41 |
| Quick ratio | 0.92 | 1.25 | 1.32 | 1.26 | 0.78 | 1.14 |
| Cash ratio | 0.34 | 0.35 | 0.50 | 0.57 | 0.13 | 0.19 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | 21.8x | 81.6x | 54.6x | -23.3x |
| Equity multiplier | 1.53 | 1.26 | 1.32 | 1.19 | 1.44 | 1.29 |
| Liabilities / Assets | 0.34 | 0.21 | 0.24 | 0.16 | 0.30 | 0.22 |
| Efficiency | ||||||
| Asset turnover | 1.92 | 0.79 | 1.01 | 1.40 | 0.80 | 0.19 |
| Inventory turnover | 2.22 | 2.64 | 3.14 | 6.05 | 4.12 | 5.31 |
| Days sales outstanding | 25d | 23d | 25d | 15d | 40d | 0d |
| Days inventory outstanding | 165d | 138d | 116d | 60d | 88d | 69d |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -1.1% | -27.7% | -10.1% | 81.4% | 492.3% | - |
| Revenue CAGR (3y) | -13.7% | 5.6% | 113.0% | - | - | - |
| Revenue CAGR (5y) | 47.2% | - | - | - | - | - |
| Gross profit growth (YoY) | -1.1% | -35.3% | -6.1% | 31.7% | 723.0% | - |
| Operating income growth (YoY) | - | - | -75.4% | 26.1% | - | -20.2% |
| Net income growth (YoY) | -1238.3% | - | -70.0% | 24.1% | - | -24.1% |
| EPS growth (YoY) | -1192.3% | - | -71.1% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | -745.1% | - | -59.6% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -66.3% | -3.4% | 12.4% | 25.8% | 27.0% | 243.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$154.83M totalHemp Products$48.06M · 31.0%
Distributors$36.72M · 23.7%
Vapes$27.05M · 17.5%
Edibles$15.13M · 9.8%
Wholesalers$10.73M · 6.9%
Flower$5.19M · 3.4%
Cartridges$4.14M · 2.7%
Non Hemp Products$3.55M · 2.3%
End Consumers$2.47M · 1.6%
Private Label Clients$1.50M · 1.0%
Customer$180.7K · 0.1%
Apparel And Accessories$106.5K · 0.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.98
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing LFTD PARTNERS INC. against the 5 most active filers in the same SIC group.